Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia

被引:11
|
作者
Petiti, Jessica [1 ]
Rosso, Valentina [1 ]
Croce, Eleonora [1 ]
Franceschi, Vanessa [1 ]
Andreani, Giacomo [1 ]
Dragani, Matteo [1 ]
De Gobbi, Marco [1 ]
Lunghi, Monia [2 ]
Saglio, Giuseppe [1 ]
Fava, Carmen [1 ]
Lo Iacono, Marco [1 ]
Cilloni, Daniela [1 ]
机构
[1] Univ Turin, San Luigi Gonzaga Hosp, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Turin, Italy
[2] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Corso Giuseppe Mazzini 18, I-28100 Novara, Italy
关键词
AML; IDH2; R140Q; R172K; PNA-PCR clamping; droplet digital PCR; diagnostic assay; POLYMERASE-CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; ONCOMETABOLITE; 2-HYDROXYGLUTARATE; EPIDEMIOLOGY; CANCER; ADULTS;
D O I
10.3390/jcm9010271
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Acute myeloid leukemia is a heterogeneous hematological disease, characterized by karyotypic and molecular alterations. Mutations in IDH2 have a role in diagnosis and as a minimal residue disease marker. Often the variant allele frequency during follow up is less than 20%, which represents the limit of detection of Sanger sequencing. Therefore, the development of sensitive methodologies to identify IDH2 mutations might help to monitor patients' response to therapy. We compared three different methods to identify and monitor IDH2 mutations in patients' specimens. Methods: Performances of PNA-PCR clamping, droplet digital PCR and Sanger for IDH2 status identification were evaluated and compared in 96 DNA patients' specimens. Results: In contrast with Sanger sequencing, our results highlighted the concordance between PNA clamping and digital PCR. Furthermore, PNA-PCR clamping was able to detect more mutated DNA with respect to Sanger sequencing that showed several false negatives independently from the allelic frequency. Conclusions: We found that PNA-PCR clamping and digital PCR identified IDH2 mutations in DNA samples with comparable results in a percentage significantly higher compared to Sanger sequencing. PNA-PCR clamping can be used even in laboratories not equipped for sophisticated analyses, decreasing cost and time for IDH2 characterization.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] IDH2 mutations in acute myeloid leukemia
    Babakhanlou, Rodrick
    DiNardo, Courtney
    Borthakur, Gautam
    LEUKEMIA & LYMPHOMA, 2023, 64 (11) : 1733 - 1741
  • [2] Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
    Brittany Knick Ragon
    Courtney D. DiNardo
    Current Hematologic Malignancy Reports, 2017, 12 : 537 - 546
  • [3] Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
    Ragon, Brittany Knick
    DiNardo, Courtney D.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (06) : 537 - 546
  • [4] Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients
    Grassi, Susanna
    Guerrini, Francesca
    Ciabatti, Elena
    Puccetti, Riccardo
    Salehzadeh, Serena
    Metelli, Maria Rita
    Di Vita, Alessia
    Domenichini, Cristiana
    Caracciolo, Francesco
    Orciuolo, Enrico
    Pelosini, Matteo
    Mazzantini, Elisa
    Rossi, Pietro
    Mazziotta, Francesco
    Petrini, Mario
    Galimberti, Sara
    CANCERS, 2020, 12 (07) : 1 - 17
  • [5] Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
    Thol, Felicitas
    Damm, Frederik
    Wagner, Katharina
    Goehring, Gudrun
    Schlegelberger, Brigitte
    Hoelzer, Dieter
    Luebbert, Michael
    Heit, Wolfgang
    Kanz, Lothar
    Schlimok, Guenter
    Raghavachar, Aruna
    Fiedler, Walter
    Kirchner, Hartmut
    Heil, Gerhard
    Heuser, Michael
    Krauter, Juergen
    Ganser, Arnold
    BLOOD, 2010, 116 (04) : 614 - 616
  • [6] Targeting the IDH2 Pathway in Acute Myeloid Leukemia
    Amaya, Maria L.
    Pollyea, Daniel A.
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 4931 - 4936
  • [7] IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
    Cerchione, Claudio
    Romano, Alessandra
    Daver, Naval
    DiNardo, Courtney
    Jabbour, Elias Joseph
    Konopleva, Marina
    Ravandi-Kashani, Farhad
    Kadia, Tapan
    Martelli, Maria Paola
    Isidori, Alessandro
    Martinelli, Giovanni
    Kantarjian, Hagop
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
    Petrova, Lucie
    Vrbacky, Filip
    Lanska, Miriam
    Zavrelova, Alzbeta
    Zak, Pavel
    Hrochova, Katerina
    CLINICAL BIOCHEMISTRY, 2018, 61 : 34 - 39
  • [9] Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
    Wouters, Bas J.
    HEMASPHERE, 2021, 5 (06): : E583
  • [10] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
    Nassereddine, Samah
    Lap, Coen J.
    Haroun, Faysal
    Tabbara, Imad
    ANNALS OF HEMATOLOGY, 2017, 96 (12) : 1983 - 1991